for use as leukocytes have been employed by Coulter for many years. It is used as a check on the performance of the instruments as well as a calibrating material. The appearance of these controls is far from the usual patient specimen, in that the colour is brownish red. On staining of a smear, the red cell morphology appears altered, with large numbers of crenocytes present. It is obvious that the cell has lost its metabolic functions.
On the other hand, a hwmatology control prepared from red cells that have not been fixed appears more like a patient specimen. The tradeoff here is that since the cell is metabolically active, as the dating of the batch progresses, there will be an increase in the mean corpuscular volume and the hematocrit will also move upward.
One problem that confronts users of Coulter semi-automated equipment is the drop in red cell counts with time after the final dilution has been made. Whether it is hamolysis of the older populations or error produced by aggregation is not clear.
(2) Leukocyte substitutes for the white cell count in the hiematology control have resulted in the addition of fixed red cells, human or avian, that will resist the lytic action and be recognized by the instrument. Nucleated avian red cells have the advantage of the larger size and the presence of a nucleus. On the other hand, the fixing procedure makes them rather sticky so that these cells must be added to the pool in a well controlled fashion in order not to produce variation in the total count. On the other hand, the use of fixed human red cells not only shows the disadvantage of stickiness but also the fact that they cannot be distinguished from the other red cells if a smear is made and stained in search of a possible explanation for unexpected results. (3) The most important problem facing the user of automated or semi-automated hiamatology controls is the lack of a stable particle suspension that may be used for standardizing the equipment independently of the electronics. Such a standard, by providing a check on number and size, would be of considerable usefulness.
Conclusion
The manufacturers of clinical chemistry and haematology controls have perhaps been reserved about manufacturing procedures or recognition of problems. Perhaps the user has considered the manufacturer as having an answer to all problems. It would appear that in legislating guidelines, careful attention should be given to recognizing those areas that require improvement, and a joint effort should be made by both the manufacturer and the user to find adequate solutions. Blood coagulation techniques may be classified into broad spectrum tests and specific clotting factor assays. There are two main systems in production of blood clotting: the tissue (extrinsic) clotting system, and the blood (intrinsic) clotting system (Fig 1) . In the extrinsic system tissue thromboplastin activates the conversion of prothrombin to thrombin. The intrinsic system is activated by surface contact.
The broad spectrum test for the extrinsic system is the prothrombin time and for the intrinsic system the partial thromboplastin (cephalin) time. It is with these two main broad spectrum tests that we will be concerned in the discussion of quality control in blood coagulation. In 1962 a system of standardization of the prothrombin time was introduced from Withington Hospital, Manchester, with the development of a standardized tissue thromboplastin reagent for local hospitals. Previously, prothrombin time results on a given blood specimen varied considerably from hospital to hospital, largely because of differences in laboratory methods, the main variable being the tissue thromboplastin used in the test, on the same blood samples, as Fig 2 shows . The results give mean values of 30 patients receiving anticoagulant treatment whose prothrombin times were expressed either as a prothrombin activity from a saline solution curve of normal plasma or as a simple relationship between the prothrombin time of the treated patient and the control, the prothrombin ratio (Fig 3) . With oral anticoagulant treatment the aim in therapy has been to lower the prothrombin activity to 15-30% of normal or, alternatively, to prolong the ratio to between 2 and 3. Thus, the average amount of anticoagulant drug prescribed in a particular hospital depended very largely on the laboratory test. In some hospitals relatively small amounts of drug were prescribed whereas, in others, relatively dangerous overdosage was inadvertently advocated.
The Manchester Comparative Reagent, as it was later designated, came to be used as reference material or for routine work in an increasing number of hospitals in the period up to 1969 when, as a result of its widespread use, it was adopted by the British Committee The quality control of the prothrombin time has two main aspects: quality control of production of the national reagent, and quality control of performance at individual hospitals.
The quality control of production of the standardized thromboplastin was based originally on the development of a method for the largescale production of a working thromboplastin preparation identical between batches. Initially, is taken in laboratory preparation of such quality control samples, to overcome the effects of activation by storage and processing and the effects of deterioration, the vials of material produced will be subject to lack of uniformity and lack of stability. Improved techniques have enabled us to produce normal and abnormal plasma samples free from intervial variation and with good stability and storage after reconstitution. The following pattern has evolved. After an advance warning, a set of three abnormal lyophilized plasmas, together with standardized thromboplastin and calcium chloride for the recalcification of the plasma samples are supplied to each hospital. They are also given an instruction sheet with the recommended technique and a form for the return of the results. The results are processed by a computer which gives a printout of the prothrombin ratio where the normal value is It was shown to be essential to provide lyophilized test plasmas. Previously, it had been assumed that all hospitals would handle the standardized thromboplastin in the same way and obtain uniform results. The quality control studies showed that this was not the case. They also showed that there is always considerable variation in results when different hospitals try to measure the prothrombin time ratio for aliquots of the same plasma with standardized thromboplastin. Although there is a tendency to obtain consistently high or low ratios on the same day of testing, there is no consistent pattern in exercises months apart.
Hospitals which used standardized reagent only occasionally for reference purposes performed less well in the trials than those which used the BCT routinely for all tests. The error in the use of the BCT with reference plasmas is appreciable but, on the basis of anticoagulant dose administration, was acceptable (Fig 6) . The true prothrombin ratio may be below 1.8 (lower limit of therapeutic range) on 5 % of occasions when the recorded ratio is 2.1, and above 3.0 on 5 % of occasions when a ratio of 2.45 is recorded. These discrepancies appear to offer reasonable safety in anticoagulant administration, particularly as hemorrhage should not be expected at prothrombin ratios below 5.0 with the BCT. The lower limit of therapy has now also been raised from a ratio of 1.8 to 2.0 to provide a greater margin of safety from inadequate anticoagulant.
The second broad spectrum test in which quality control is being attempted is the partial thromboplastin time. This test is used both for oral anticoagulant and heparin control, but mainly as a screening test for defects of intrinsic blood coagulation such as occur in haemophilia and Christmas disease. The test suffers from the same lack of standardization and variability of results with different reagents as did the prothrombin time. Most of the reagents used in laboratories are commercially manufactured from animal tissues and many of these are grossly insensitive, that is, fail to pick out quite severe cases of hlemophilia. A standardized material was developed aiming to provide the maximum sensitivity to the human intrinsic clotting defect. A large batch has been laid down in lyophilized form at low temperatures as a primary standard. The standardized reagent has been provided to hospitals at home and abroad for a current quality control trial and for reference or routine work. A similar procedure has been adopted to the prothrombin time studies, with the supply of a set of three abnormal plasmas, standardized cephalin, other reagents required in the test and a recommended technique. One of the abnormal plasmas in the current trial represents a very slight clotting defect, the second a moderate coagulation defect, and the third quite severe. The results are being analyzed but all the hospitals appear to handle the standardized preparation with good results whereas the results with the commercial preparations are very variable. One widely available commercial reagent has consistently failed to pick out even the severe degree of clotting defect.
The British system for anticoagulant control has been until recently the only national system developed for the coordination of anticoagulant control. WHO 
Quality Control in Blood Transfusion
The purpose of quality control in blood transfusion is to ensure the maximum safety of the blood donor and of the recipient of a transfusion, the term embracing the surveillance of the procedures involved at all stages, including the collection of blood, serological tests performed and the actual administration of the transfusion. The various points to be watched may be conveniently listed as follows: (1) Quality of taking and giving apparatus. Apart from the quality of glassware and plastics used, the condition of the blood itself is most important. It must be free from hamolysis and bacterial infection, it must have been stored at a suitable temperature, while it must be of the blood group stated on the label. All serological investigations to determine blood groups and freedom from syphilis must have been performed with suitable reagents and by reliable techniques. All documentation in both regional transfusion centre and hospital laboratory must be correct and must be available for inspection should this be necessary. Finally, every care must be taken in the ward to see that the patient receives only the blood supplied for him. In this paper mention will be made only of proficiency testing of serology and briefly of reagent control. Although these are two different matters, they do overlap to some extent.
